Prot #CLEE011X2105: A Phase Ib/II, Multicenter, Study of LEE011 in Combination with LGX818 in Adult Patients with BRAF Mutant Melanoma

    Project: Research project

    Project Details

    StatusFinished
    Effective start/end date1/1/136/30/15

    Funding

    • Novartis Pharmaceuticals Corporation (Prot #CLEE011X2105)